#DrugDocs
LightNews LightNews
drugdocs.bsky.social
Top 3 drugs searched on DRUGDOCS® in November:

1. Tezspire®: Severe asthma biologic

2. Zolymbus®: Glaucoma eye treatment

3. Sovaldi®: Chronic hepatitis C antiviral

Explore the clinical evidence behind these drugs and more at drugdocs.com

#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
December 12, 2025 at 3:51 PM
drugdocs.bsky.social
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.

💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1

🔗 Read more here: www.who.int/news/item/01...

#GLP1 #PublicHealth #DRUGDOCS
December 8, 2025 at 4:23 PM
drugdocs.bsky.social
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
December 5, 2025 at 10:10 PM
drugdocs.bsky.social
FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
November 14, 2025 at 8:13 PM
drugdocs.bsky.social
It’s #WorldDiabetesDay, a day to raise awareness, improve access to care, and advance research in the fight against diabetes.

DRUGDOCS® gives you quick access to clinical evidence on treatments for diabetes, from insulin to SGLT2s & GLP-1s.
Start searching: drugdocs.com/search/diabe...
November 14, 2025 at 3:14 PM
drugdocs.bsky.social
Top 3 drugs searched on DRUGDOCS® in October:
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
November 11, 2025 at 3:35 PM
drugdocs.bsky.social
Bayer’s Lynkuet (elinzanetant) has received FDA approval to treat moderate to severe vasomotor symptoms including hot flashes and night sweats, during menopause.

🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet

#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
November 7, 2025 at 3:47 PM
drugdocs.bsky.social
JAMA+ Women’s Health, a new hub for sex-specific evidence in every specialty, has launched!
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com
October 30, 2025 at 5:46 PM
drugdocs.bsky.social
The FDA has approved Jascayd® (nerandomilast tablets), the first new treatment in mover than 10 years for idiopathic pulmonary fibrosis. Jascayd slowed lung function decline in trials, offering new hope for this serious, progressive disease.

🔬 Find the clinical data at DRUGDOCS.
DRUGDOCS | Jascayd®
drugdocs.com
October 23, 2025 at 1:47 PM
drugdocs.bsky.social
FDA approves the Elecsys blood test to aid Alzheimer’s diagnosis. The test helps rule out the disease with 97.9% accuracy and may increase access to treatments like Leqembi and Kisunla.

📖 Read more below.

🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...
www.reuters.com
October 21, 2025 at 5:32 PM
drugdocs.bsky.social
It's World Evidence-Based Health Care Day!

At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.

We’re proud to support this mission because informed prescribing starts with trusted information.

🔗 worldebhcday.org
October 20, 2025 at 7:15 PM
drugdocs.bsky.social
🔍 Top 3 most searched drugs on DRUGDOCS in September:

1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis

📖 Find the evidence @ drugdocs.com
October 6, 2025 at 8:11 PM
drugdocs.bsky.social
FDA has approved Forzinity for Barth syndrome, the first-ever treatment for this rare mitochondrial disease.
Approval is based on improved leg muscle strength, offering new hope for patients.
📖 Clinical evidence at @DRUGDOCS drugdocs.com/drug/Forzinity
🔗 Read more here: www.fda.gov/news-events/...
October 2, 2025 at 7:45 PM
drugdocs.bsky.social
📢 Merck’s Capvaxive, built for seniors, is proving effective in kids too.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile

🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.
Despite being designed for seniors, Merck's pneumococcal shot shows potential in children
Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data
www.fiercepharma.com
September 23, 2025 at 8:09 PM
drugdocs.bsky.social
FDA approves Tonmya, the first new fibromyalgia treatment in over 16 years. Clinical trials showed reduced pain and improved sleep in nearly 1,000 patients.

📊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/drug/Tonmya

🔗 Read more: www.fiercepharma.com/pharma/tonix...
September 12, 2025 at 6:59 PM
drugdocs.bsky.social
📈 Trending on DRUGDOCS® in August 2025:
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com
September 4, 2025 at 6:49 PM
drugdocs.bsky.social
Brinsupri achieves FDA approval as the 1st treatment for non-cystic fibrosis bronchiectasis. It also launches the novel DPP1 inhibitor class, blocking enzymes that fuel harmful lung inflammation. Big news for chronic lung disease.

💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri
August 21, 2025 at 10:48 PM
drugdocs.bsky.social
New NSCLC approval: FDA clears Zegfrovy (sunvozertinib) for EGFR exon 20+ disease after progression on platinum chemotherapy.

Key findings from the WU-KONG1B study:
✔️ 46% overall response rate
✔️ Median duration of response: 11.1 months

Explore the evidence on DRUGDOCS®: drugdocs.com/drug/Zegfrovy
August 14, 2025 at 3:53 PM
drugdocs.bsky.social
It’s Psoriasis Awareness Month! Psoriasis affects 125 million people globally, with serious comorbidities such as cardiovascular disease and depression.

Explore the clinical evidence for 18 approved treatments on DRUGDOCS® and stay informed to support better care: drugdocs.com/search/psoriasis
August 12, 2025 at 5:54 PM
drugdocs.bsky.social
What captured your attention on DRUGDOCS® in July?
1️⃣ Yeztugo® for chronic myeloid leukemia
2️⃣ Yorvipath® to slash LDL-C via PCSK9 inhibition
3️⃣ Lynozyfic® GLP-1 agonist for type 2 diabetes

🔍 All the data, all the studies, right here: drugdocs.com
#Yeztugo #Yorvipath #Lynozyfic
August 5, 2025 at 6:48 PM
drugdocs.bsky.social
Biotech is navigating market uncertainty, but H2 2025 could bring much-needed momentum. Major trial results are expected, and obesity, Alzheimer’s, MS, and eczema are all in focus.

📖 Read about the trials to watch below.

As new drugs are approved, visit DRUGDOCS® for the current best evidence.
10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and AATD headline a series of study results that could give the biotechnology sector a boost.
www.biopharmadive.com
July 30, 2025 at 2:09 PM
drugdocs.bsky.social
FDA okays Ekterly®, the first oral on-demand treatment for hereditary angioedema.
The Phase 3 trial demonstrated much faster symptom relief vs. placebo and a strong safety profile.

🔗 Read more: www.pharmexec.com/view/fda-app...

💊 Explore the clinical data at @DRUGDOCS®: drugdocs.com/drug/Ekterly
July 24, 2025 at 8:53 PM
drugdocs.bsky.social
📊 June 2025’s top searches on DRUGDOCS®:
1️⃣ Andembry® – monthly FXIIa inhibitor for hereditary angioedema
2️⃣ Emrelis™ – c MET antibody-drug conjugates for advanced non squamous NSCLC.
3️⃣ Nucala® – anti–IL 5 for eosinophilic asthma, COPD, and more.
🔍 See the clinical data at DRUGDOCS® drugdocs.com
July 8, 2025 at 2:26 PM
drugdocs.bsky.social
Happy 4th of July from DrugDocs!
Here’s to the spirit of innovation, freedom, and progress in healthcare and beyond.

#FourthOfJuly #IndependenceDay
July 4, 2025 at 2:32 PM
drugdocs.bsky.social
Today is #WorldSickleCellDay. Join the global effort to support the 7.7M people living with sickle cell disease worldwide.
Find info and events here: www.sicklecelldisease.org/get-involved...
Find clinical data for drug treatments at DRUGDOCS: drugdocs.com/search/sickl...
World Sickle Cell Day - Sickle Cell Disease Association of America Inc.
June 19 is World Sickle Cell Awareness Day. The international awareness day is observed annually with the goal to increase public knowledge and an understanding of sickle cell disease, and the challen...
www.sicklecelldisease.org
June 19, 2025 at 1:59 PM